Author Archives: Scalper1

The Stock Market, From A Variety Of Viewpoints: Financial Advisors’ Daily Digest

SA Dividends, Income & Retirement Editor Robyn Conti here, subbing in for Gil, who’s observing Passover this week. I’ll do my best to fill his very talented and knowledgeable shoes and continue to keep you up to date daily on the latest FA analysis and news here on Seeking Alpha. Today’s FA Digest deals with different ways of looking at the stock market, but before we jump in, I wanted to thank you for accompanying me this week. It’s been my pleasure to bring you a variety of topics of interest to financial advisors, and I hope you enjoyed this week’s posts. Gil will be back in the captain’s chair next week. And now, on to today’s stories… In The Stock Market Is Not A Slot Machine, Nor A Vending Machine , Peter F. Way, CFA , presents a multi-faceted view of the markets from a behavioral finance and market makers’ perspective. He writes: Constant change keeps the market churning. Change in technology, change in competition, change in consumer attitudes, desires, change in opportunities, change in risk exposures, threats. What doesn’t change? Human nature, behavior. Financial markets anticipate, as well as react. To deal with both conditions participants must make forecasts. Good forecasts need GOOD information. GOOD information is not to be found in MIS-information – the deluge of largely irrelevant minutia flooding the print and electronic media that tells you what you already know (or think you know) – and “interesting” tidbits that distract, but are not relevant to what you need to know. BAD information – DIS-information – is intentionally misleading falsehoods, usually cleverly disguised and presented at times and in ways to get you to do what will help others while hurting you. Value transferred, not created. Peter then goes on to dissect how the market maker community assists big money managers in making timely trades, and provides an example of how their practices work by discussing how they view Constellation Brands (NYSE: STZ ). The bottom line: Advisors and investors need to pay attention to a variety of factors, from the potential for price changes to analyzing alternative options to when investments are made. Not rocket science, to be sure, but definitely an interesting and compelling point of view from someone with intimate knowledge of how market makers help engineer trades and move markets, and how they impact individual investors as a result. Charles Schwab offers a different perspective, offering a look at exit strategies from a technical and charting angle. In Pulling The Trigger: 3 Exit Strategy Philosophies , they prescribe three different types of exits: 1. Find support and resistance zones, 2. Let your profits run, and 3. Take profits (but not necessarily all of them). It’s a bit of a departure from the typical fundamental focus of most SA authors, but no less valuable and useful for advisors and investors who like to incorporate technical analysis and charting into their strategies. Providing more of a 30,000-foot-view of the markets, William Koldus, CFA, CAIA , hypothesizes that, like all good things, the bull market we’ve enjoyed for so many years may, indeed, be coming to an end. He cites underwhelming Q1 earnings, emerging inflation, and soaring share prices returning to reality as reasons the bull market may be winding down. His thesis? “Investors should turn their focus to late stage cyclical plays, as the bulk of the gains for the broader equity market have been achieved in the current bull market.” And from the world of retirement planning and money management, George Schneider discusses self-sabotaging behaviors that often plague investors as they find ways to procrastinate saving for retirement, and suggests a variety of common-sense solutions for turning the ship around, such as prolonging one’s working years, saving early and often, and leveraging employer-sponsored retirement plans and other savings vehicles like traditional IRAs. Of course, the underlying message is that advisors have an opportunity to help clients right their retirement ships by making smart, informed decisions about their money and portfolios, making for smooth sailing into their happy golden years. And finally, we continue to keep watchful eye on the economy here at Seeking Alpha. As such, here’s some of the latest news and views: Tim Duy warns the Fed may shed its dovish feathers and reveal a more hawkish approach going forward . James Picerno writes that next week’s April jobs report will impact whether markets remain bullish or take a bearish turn. Eric Parnell takes a look at the good signs, and the not-so-good ones, for the U.S. economy going forward. Comstock dissects past Fed moves, and speculates on how future Fed decisions may impact stocks.

How LinkedIn Turned A Bad Business Situation Into Good

It was a shocking day for LinkedIn ( LNKD ) when the business networking company reported fourth-quarter earnings on Feb. 4 that led to a 44% plunge in its stock price. In its Q4 earnings conference call, LinkedIn executives revealed a company reshuffling that had many observers scratching their heads. Analysts slashed price targets as LinkedIn announced it would shutter a unit worth about $50 million in revenue, a move one analyst called a “gigantic mistake.” Apparently it wasn’t. LinkedIn committed new resources toward newer products that cashed in when the company reported first-quarter earnings  after the close Thursday that walloped expectations. LinkedIn reported Q1 revenue of $860.7 million, up 35% year over year and beating the consensus of $828.5 million. Earnings per share minus items rose 30% to 74 cents, beating the consensus of 60 cents, as polled by Thomson Reuters. Its guidance also exceeded views. “We believe LinkedIn righted its ship with a solid first-quarter upside and raised guidance,” wrote Needham analyst Kerry Rice, who maintained a buy rating and price target of 200. Many of the issues LinkedIn revealed were not as severe as expected, Rice wrote in a research note. LinkedIn generates revenue from three business segments. Revenue from Talent Solutions, which gets fees from companies and headhunters seeking hires, rose 41% to $558 million. Revenue from Marketing Solutions, which sells ads, increased 29% to $154 million. Revenue from Premium Subscriptions increased 22% to $149 million. In its reshuffling, LinkedIn created products such as Referrals and Connectifier, online platforms that help customers drive a greater share of hiring through LinkedIn. In its Marketing Solutions unit, LinkedIn redoubled its focus on Sponsored Content. which provides targeted advertising that appears in the feeds of social platforms on LinkedIn. These new products and others were a significant contributor that helped LinkedIn beat expectations. Sponsored Content revenue rose 80% and is the fastest-growing segment of Marketing Solutions, LinkedIn said. “LinkedIn posted Q1 upside across every business unit,” wrote Pacific Crest analyst Evan Wilson in a report. “We are confident in LinkedIn’s uniquely valuable data set and think the company has set itself up for further upside over the balance of the year.” Wilson has a overweight rating on LinkedIn stock and a price target of 190. Jefferies has a buy rating and price target of 180. RBC Capital Markets has a market perform rating and price target of 160. Nomura has a buy rating and price target of 180. LinkedIn stock was up 3%, near 126.50, in afternoon trading in the stock market today . Since the 44% plunge three months ago, LinkedIn stock is up 15%. Image provided by Shutterstock .

Gilead Sciences Takes Lumps From Wall Street After Q1 Miss

Big biotech Gilead Sciences ( GILD ) got a downgrade and several price-target cuts Friday after its Q1 report missed expectations , sending its stock tumbling. Maxim Group analyst Jason Kolbert downgraded Gilead to hold from buy, noting that the record-breaking launches of hepatitis C drugs Sovaldi and Harvoni were coming up against competition and tough year-over-year comparisons. “New patient numbers increased … but product margins per patient were lower as a result of: 1) increased HCV price competition ( Merck ‘s ( MRK ) Zepatier); 2) an increased discount rate; and 3) higher-than-expected rebate claims,” Kolbert wrote in his research note. “While management believes that HCV products have stabilized (the U.S. market share is at about 90%), we are not so sure.” Leerink analyst Geoffrey Porges lowered his price target on Gilead to 123 from 127 but maintained an outperform rating. He noted that the company still has a huge reserve of cash, and wrote that the HCV franchise was eroding earlier then expected but it was presumed to decline in a few years anyway. “As a result, our EPS estimates fall 8%-10% through 2017, but only 3% beyond,” he wrote in his research note. UBS analyst Marc Goodman also kept his buy rating while lowering his price target to 118 from 130, writing that he’s “willing to have a little patience.” “The (HCV) category still has years ahead of stable patients,” Goodman wrote. “The issue remains; what’s next? … At this valuation, we will try to remain patient.” Gilead stock was down 7.5% in afternoon trading on the stock market today , below 90. On the positive side for Gilead, the company said Friday that the EU’s Committee for Medicinal Products for Human Use, which advises Europe’s equivalent of the FDA, had endorsed approving Odefsey, the company’s newest four-drug combo pill for HIV. The combo includes TAF, known on Wall Street as “son of Viread” as it represents an upgraded version of Gilead’s legacy blockbuster Viread, which is due to go off patent in the near future.